Modulation o f tissue exposure to cortisol, new perspective for reducing the metabolic risk associated with obesity;Moduler l'exposition tissulaire au cortisol, nouvelle perspective pour réduire le risque métabolique associé à l'obésité

Revue Medicale de Liege

Volumn 65, Issue 3, 2010, Pages 140-146

  Iovino, A ^a   Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

11 Beta hydroxysteroid dehydrogenase type 1; Abdominal obesity; Cortisol; Metabolic syndrome; Type 2 diabetes

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; CORTISONE; HYDROCORTISONE;

ABDOMINAL OBESITY; ADIPOSE TISSUE; DRUG EXPOSURE; ENZYME ACTIVITY; HUMAN; HYPERCORTISOLISM; INSULIN RESISTANCE; METABOLIC SYNDROME X; MODULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; RISK ASSESSMENT;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADIPOSE TISSUE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-OBESITY AGENTS; CORTISONE; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HUMANS; HYDROCORTISONE; METABOLIC SYNDROME X; OBESITY; OBESITY, ABDOMINAL; TREATMENT OUTCOME;

EID: 77951078546     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Scheen AJ. - L'«épidémie» des maladies métaboliques, un problème majeur de santé publique. Rev Med Liège, 1999, 54, 87-94.
2. Després JP. - Is visceral obesity the cause of the metabolic syndrome? Ann Med, 2006, 38, 52-63.
3. Björntorp P, Rosmond R. - Obesity and cortisol. Nutrition, 2000, 16, 924-936.
4. Anagnostis P, Athyros VG, Tziomalos K, et al. - The pathogenetic role of cortisol in the metabolic syndrome: A hypothesis. J Clin Endocrinol Metab, 2009, 94, 2692-2701.
5. Tomlinson J W, Walker EA, Bujalska IJ, et al. - 11β- hydroxysteroïd dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev, 2004, 25, 831-866.
6. Bujalska IJ, Draper N, Michailidou Z, et al. - Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11 beta-hydoxysteroid dehydrogenase type 1. J Mol Endocrinol, 2005, 34, 675-684.
7. Bujalska IJ, Walker EA, Hewison M, et al. - A switch in dehydrogenase to reductase activity of 11β-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J Clin Endocrinol Metab, 2002, 87, 1205-1210.
8. Stulnig TM, Waldhäusl W. - 11β-hydroxysteroid dehy-drogenase type 1 in obesity and type 2 diabetes. Diabe-tologia, 2004, 47, 1-11.
9. Iovino A, Paquot N, Scheen AJ. - Rôle de l'enzyme 11β-hydroxystéroïde déshydrogénase de type 1 dans le risque métabolique associé à l'obésité. Obésité, 2009, 4, 181-188.
10. Walker BR, Andrew R. - Tissue production of cortisol by 11β-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann NY Acad Sci, 2006, 1083, 165-184.
11. London E, Castonguay TW. - Diet and the role of 11β-hydroxysteroid dehydrogenase-1 on obesity. J Nutr Biochem, 2009, 20, 485-493.
12. Iwasaki Y, Takayasu S, Nishiyama M, et al. - Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11β-hydroxysteroid dehydrogenase type 1) gene. Mol Cell Endocrinol, 2008, 285, 10-18.
13. ère partie: rôle de l'exposition tissulaire au cortisol dans le risque métabolique lié à l'obésité. Méd Malad Métab, 2010, 4, sous presse.
14. ème partie: Inhibition sélec-tive pour traiter les anomalies métaboliques associées à l'obésité. Méd Malad Métab, 2010, 4, sous presse.
15. Bujalska IJ, Kumar S, Stewart PM. - Does central obesity reflect "Cushing's disease of the omentum"? Lancet, 1997, 349, 1210-1213.
16. Tomlinson J W, Stewart PM. - «Cushing's disease of the omentum» fact or fiction? J Endocrinol Invest, 2004, 27, 171-174.
17. Stimson RH, Andersson J, Andrew R, et al. - Cortisol release from adipose tissue by 11β-hydroxysteroid dehy-drogenase type 1 in humans. Diabetes, 2009, 58, 46-53.
18. Swali A, Walker EA, Lavery GG, et al. - 11beta-hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets. Diabetolo-gia, 2008, 51, 2003-2011.
19. Berthiaume M, Laplante M, Festuccia WT, et al. - Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats. Int J Obes, 2009, 33, 601-604.
20. Baudrand R, Carvajal CA, Riquelme A, et al. - Overex-pression of 11beta-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients. Obes Surg, 2010, 20, 77-83.
21. Rask E, Olsson T, Söderberg S, et al. - Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab, 2001, 86, 1418-1421.
22. Stewart PM, Boulton A, Kumar S, et al. - Cortisol metabolism in human obesity: impaired cortisone cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab, 1999, 84, 1022-1027.
23. Rask E, Walker BR, Söderberg S, et al. - Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydro-genase type 1 activity. J Clin Endocrinol Metab, 2002, 87, 3330-3336.
24. Alberti L, Girola A, Gilardini L, et al. - Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase type 1 in obese subjects. Int J Obes, 2007, 31, 1826-1831.
25. Veilleux A, Rhéaume C, Daris M, et al. - Omental adipose tissue 11{beta}-HSD1 oxoreductase activity, body fat distribution and metabolic alterations in women. J Clin Endocrinol Metab, 2009, 94, 3550-3557.
26. Sandeep TC, Andrew R, Homer N Z M, et al. - Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes, 2005, 54, 872-879.
27. Basu R, Singh RJ, Basu A, et al. - Obesity and type 2 diabetes do not alter splanchnic cortisol production in humans. J Clin Endocrinol Metab, 2005, 90, 3919-3926.
28. Stimson RH, Andersson J, Andrew R, et al. - Cortisol release from adipose tissue by 11β-hydroxysteroid dehy-drogenase type 1 in humans. Diabetes, 2009, 58, 46-53.
29. Andrew R, Westerbacka J, Wahren J, et al. - The contribution of visceral adipose tissue to splanchnic corti-sol production in healthy humans. Diabetes, 2005, 54, 1364-1370.
30. Basu R, Basu A, Grudzien M, et al. - Liver is the site of splanchnic cortisol production in obese nondiabetic humans. Diabetes, 2009, 58, 39-45.
31. Stewart PM, Tomlinson JW. - Selective inhibitors of 11β- hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome, is the target liver, fat, or both? (commentary). Diabetes, 2009, 58, 14-15.
32. Valsamakis G, Anwar A, Tomlinson JW, et al. - 11β-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab, 2004, 89, 4755-4761.
33. Boyle CD, Kowalski TJ. - 11beta-hydroxysteroid dehy-drogenase type 1 inhibitors: a review of recent patents. Exp Opin Ther Pat, 2009, 19, 801-825.
34. Hawkins M, Hunter D, Kishore P, et al. - INCB013739, a selective inhibitor of 11β-hydroxysteroid dehydroge-nase type 1 (11βHSD1), improves insulin sensitivity and lowers plasma cholesterol over 28 days in patients with type 2 diabetes mellitus (Abstract). Diabetes, 2008, 57 (Suppl 1), A99-A100.
35. Rosenstock J, Banarer S, Fonseca V, et al. - Efficacy and safety of the 11-β-HSD1 inhibitor, INCB13739, added to metformin therapy in patients with type 2 diabetes (abstract). Diabetes, 2009, 59, late breaking abstract 7-LB.
36. Vantyghem MC, Marcelli-Tourvieille S, Defrance F, et al. - 11β-hydroxystéroïde déshydrogénases. Avancées récentes. Ann Endocrinol Paris, 2007, 68, 349-356.
37. Hwang JY, Lee SH, Kim GS, et al. - HSD11B1 polymorphisms predicted bone mineral density and fracture risk in postmenopausal women without a clinically apparent hypercortisolemia. Bone, 2009, 45, 1098-1103.
38. Wamil M, Seckl JR. - Inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov Today, 2007, 12, 504-520.
39. Strachan M W J, Reynolds RM, Frier BM, et al. - The role of metabolic derangements and glucocorticoid excess in the aetiology of cognitive impairment in type 2 diabetes. Implications for future therapeutic strategies. Diabetes Obes Metab, 2009, 11, 407-414.